Recent advances in nutraceuticals and functional foods to treat obesity-associated non-alcoholic fatty liver disease

Obesity and its accompanying non-alcoholic fatty liver disease (NAFLD) morbidity rates, which are connected with lipid metabolism-related issues, have evolved as a major concern with advancements in global agricultural production and trade networks. Obesity is a major contributor to the development of NAFLD, which is linked to metabolic diseases. The purpose of this review is to shed light on how functional dietary alterations affect liver condition and, to a lesser degree, glucose metabolism in overweight or obese patients with NAFLD. NAFLD is characterized by liver abnormalities that can develop into liver fibrosis and cirrhosis. The cause and course of NAFLD are unclear; however, it is thought to reflect the metabolic syndrome's hepatic component. NAFLD and chronic liver disease can only be treated and avoided using safe, effective, and diversified therapeutic agents, and their development is urgently needed. A growing body of data backs up interventional techniques that include nutraceuticals and functional meals, which have gained a lot of attention. Prevention and treatment of obesity utilizing organically derived chemicals are desirable in the nutraceutical and functional food industries in terms of marketing and safety. Nutraceutical studies investigating the efficacy in treating obesity and its accompanying NAFLD may result in weight loss and a drop in liver enzymes.